Luke McFarlane

Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.

Natural MedTech is manufacturing psychedelic medicines to unlock neurologic potential. We are building Australia’s leading pure-play psychedelic business, with differentiated IP, an experienced team, and a self-funding growth profile.

Long only digital asset fund focused on listed Web3 tokens Partners have a combined 35 years experience in global capital markets Proprietary institutional investment process and risk management framework Tier one partnerships provide institutional technical, audit, legal and compliance oversight

Ezel.Life brings time, culture and humanity to Web3 through immersive experiences, education and gaming. First launch Frida Kahlo Red House metaverse.

Balyasny Asset Management (BAM) is a diversified global investment firm founded in 2001 by Dmitry Balyasny, Scott Schroeder, and Taylor OMalley. With over $33 billion in assets under management, BAM employs more than 2,500 people across 23 offices in the U.S. and Canada, Europe, the Middle East, and Asia. The firm’s investment teams span five strategies, including Equities Long/Short, Fixed Income & Macro, Commodities, Multi-Asset Arbitrage, and Systematic. Balyasny’s mission is to deliver to its investors absolute, uncorrelated returns in all market environments.

At Macquarie, we empower people to innovate and invest for a better future. We are a global financial services organisation with Australian heritage, operating in 30 markets. To find out more, visit us at www.macquarie.com To read our social media disclaimer, visit macq.co/SocialMediaDisclaimer